Glaxo Unveils Positive Data for Potential Blockbuster Anemia Drug
(Bloomberg) -- GlaxoSmithKline Plc released positive trial results for a potential blockbuster anemia pill the company is hoping will bolster its pharma portfolio as the drugmaker prepares to spin off its consumer healthcare business next year.
Results from five studies found the oral treatment for patients with anemia due to chronic kidney disease either maintained or improved hemoglobin levels compared with current medication, without increasing the cardiovascular risk, according to data presented Friday.
The data make Glaxo a contender for one of the first anemia treatments in pill form for both dialysis and non-dialysis patients in the U.S. and Europe. The company had been lagging behind two other similar treatments from AstraZeneca Plc and its partner FibroGen Inc., and Akebia Therapeutics Inc. and partner Otsuka Pharmaceutical Co., but both have suffered setbacks over the last 18 months.
More than 700 million people globally suffer from chronic kidney disease, with one in seven estimated to develop anemia. Patients must currently undergo injections to manage the condition. Glaxo is hoping its oral drug - daprodustat - will be among a new line-up of key money-makers for its revamped pharma and vaccines company after it separates from its consumer arm in mid-2022.
In June, the company told investors it was forecasting annual sales of between 500 million pounds ($673 million) and 1 billion pounds. Glaxo first released high-level positive results from the trials in July.
There's an opportunity “with an oral drug for the patients to, in some aspects, take a little bit more control of their disease because they're no longer reliant at least for the anemia to have to go in to see the healthcare provider for an injection,” Chris Corsico, Glaxo's head of development, said in an interview.
The data published Friday crucially shows the drug has no increased heart risk for dialysis or non-dialysis patients compared to an erythropoietin stimulating agent -- an injection that is the current standard of care. This has been one of the issues hampering other drugmakers, giving rise to concerns cardiovascular side effects could be a class-wide issue for the drug type.
The treatments from Glaxo and its rivals have already been approved in Japan, where regulators don't require data on the cardiovascular impact, as well as some other markets. None has yet secured authorization in the U.S. or Europe. Akebia has applied for approval from the U.S. Food and Drug Administration and a decision is expected by the end of March. Glaxo is planning to submit its results to regulators globally in coming months.
©2021 Bloomberg L.P.
-
One El Nino, India Can Handle. Two Could Break The Granary
India's grain stocks can absorb one bad year, but a second El Nino could drain the buffer in two to three years, economists say.
-
India's Troika Of Good Luck | Joining The Dots
As Jensen Huang's exit drags Nvidia down, a cooling AI trade and resilient earnings have revived investor interest in India. A likely RBI rate hike looms.
-
Talking Points This Week: Leadership Shock At Nvidia, Earnings Strength, And The Fog Over Hormuz
The Anthropic IPO pricing and first trading day, Nvidia's upcoming earnings, and any fresh signals from Iran will set the tone for the following week.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.